Table 1.

JNJ-28312141 reduced the growth of H460 tumors, diminished TAMs and microvasculature, and elevated plasma CSF-1

Dose* JNJ-28312141, mg/kgJNJ-28312141 plasma levels, ng/mLMean final tumor weight, mgMacrophage density, % areaMicrovascular density, % area§Plasma CSF-1, pg/mL (human) Plasma CSF-1, pg/mL (mouse)
001,584 ± 25710.6 ± 1.833.66 ± 0.8501,345 ± 63
25243 ± 371,257 ± 2094.3 ± 0.683.73 ± 0.81217 ± 891,770 ± 73
50594 ± 441,070 ± 1212.6 ± 0.572.10 ± 0.57396 ± 761,722 ± 98
1001159 ± 77870 ± 940.31 ± 0.141.25 ± 0.16778 ± 2532,293 ± 88

NOTE: Values represent means ± SEM (n = 15).

  • *Twice daily (except once daily on weekends) oral dosing commenced 3 d after s.c. inoculation of H460 lung adenocarcinom cells and continued until sacrifice on day 28.

  • Plasma levels of JNJ-28312141 were determined 2 h after the final dose administration on day 28.

  • Percentage of area determined to be F4/80 positive.

  • §Percentage of area determined to be CD31 positive.

  • P < 0.01 versus control.

  • P < 0.05 versus control.